Price
No data yet.
Social Signal Score
Analyst Ratings
19 analystsRevenue
$28.53M+152.72%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gregory A. Demopulos
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 175
- Beta
- 2.60
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 0.29
Financials
Revenue
$28.53M+152.7%Net Income
$13.23MEBITDA
$17.58MFree Cash Flow
$4.10MEPS (diluted)
$0.15Shares Outstanding (diluted)
89.63M+118.3%Operating Expenses
$27.66MCash & Debt
$131.95MReturn of Capital
$1.62MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-3.35M | $-0.05 |
| 2024 | $0.00 | $-156.81M | $-2.70 |
| 2023 | $0.00 | $-117.81M | $-1.88 |
| 2022 | $0.00 | $47.42M | $0.46 |
| 2021 | $0.00 | $-111.41M | $-1.79 |
| 2020 | $0.00 | $-138.06M | $-2.41 |
| 2019 | $111.81M | $-84.49M | $-2.16 |
| 2018 | $29.87M | $-126.76M | $-2.61 |
| 2017 | $64.83M | $-53.48M | $-1.17 |
| 2016 | $41.62M | $-66.75M | $-1.65 |
| 2015 | $13.51M | $-75.10M | $-2.00 |
| 2014 | $539.0K | $-73.67M | $-2.22 |
| 2013 | $1.60M | $-39.80M | $-1.39 |
| 2012 | $6.02M | $-38.44M | $-1.59 |
Valuation
OMERhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
57+13.33%Social Signal Score
Mentions (7)
- Newsbenzinga.com·13d ago·Neutral
Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst Cantor Fitzgerald on Tuesday upgraded Omeros Corp (NASDAQ:OMER), citing a better-than-expected Yartemlea launch.
View source ↗ - Newszacks.com·38d ago·Positive
What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now? Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newsdefenseworld.net·52d ago·Positive
Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Brokerages Shares of Omeros Corporation (NASDAQ: OMER - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six analysts that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·54d ago·Neutral
Omeros Q2 Earnings Call Highlights Omeros NASDAQ: OMER reported second-quarter net sales of $28.5 million for YARTEMLEA, its newly launched treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA, as the company generated positive operating cash flow and reduced its convertible debt after the quarter ended.
View source ↗ - Newszacks.com·54d ago·Neutral
Omeros (OMER) Q2 Earnings and Revenues Beat Estimates Omeros (OMER) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to a loss of $0.53 per share a year ago.
View source ↗ - Newsbusinesswire.com·57d ago·Neutral
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026 SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the second quarter of 2026 on Wednesday, August 12, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Confer
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.05 per share
Typical surprise +30.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$0.15 vs $-0.27beat
- Wed, May 13$-0.24 vs $-0.40beat
- Tue, Mar 31$3.14 vs $-0.55beat
- Thu, Nov 13$-0.47 vs $-0.58beat
- Thu, Aug 14$-0.43 vs $-0.55beat
- Thu, May 15$-0.58 vs $-0.57miss
Estimates and results for OMER via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OMER officers and directors.
- Bought
- $41k
- Sold
- $2.8m
2 trades
13 trades
- Borges David J.sold
- Cancelmo Peter Bsold
- Cancelmo Peter Bsold
- Hanish Arnold Csold
- Hanish Arnold Csold
- Hanish Arnold Csold
- Borges David J.sold
- Borges David J.sold
85 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in OMER.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.